Table 1.

Summary of patients' pretreatment characteristics

No. of patients 25  
 Men 9 
 Women 16  
Age, y  
 Median 46 
 Range 22-74  
Baseline platelet count, × 109/L  
 Median 13 
 Range 3-25  
Previous therapies  
 Prednisone* 25  
 Intravenous immunoglobulin 25  
 High-dose dexamethasone 11 
 Splenectomy 8  
 Vincristine† 5  
 Pulse cyclophosphamide 4  
 Vitamin C 2  
 Anti-Rh globulin 1 
ITP duration before rituximab treatment, mo  
 Median 22 
 Range 9-56  
Elevated PAIgG 19/19 
Elevated ACA/LLA 11  
ANA positive 0  
Coombs tests positive 0 
No. of patients 25  
 Men 9 
 Women 16  
Age, y  
 Median 46 
 Range 22-74  
Baseline platelet count, × 109/L  
 Median 13 
 Range 3-25  
Previous therapies  
 Prednisone* 25  
 Intravenous immunoglobulin 25  
 High-dose dexamethasone 11 
 Splenectomy 8  
 Vincristine† 5  
 Pulse cyclophosphamide 4  
 Vitamin C 2  
 Anti-Rh globulin 1 
ITP duration before rituximab treatment, mo  
 Median 22 
 Range 9-56  
Elevated PAIgG 19/19 
Elevated ACA/LLA 11  
ANA positive 0  
Coombs tests positive 0 

ITP indicates idiopathic thrombocytopenic purpura; PAIgG, platelet-associated IgG; ACA/LLA, anticardiolipin antibodies/lupuslike anticoagulant; ANA, antinuclear antibodies.

*

1 to 2 mg · kg−1 · d−1.

†

2 mg/wk × 4.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal